Riverton, IL, United States of America

Sophia Ran

USPTO Granted Patents = 22 


 

Average Co-Inventor Count = 2.5

ph-index = 10

Forward Citations = 418(Granted Patents)


Location History:

  • Riverton, IL (US) (2007 - 2011)
  • Dallas, TX (US) (2001 - 2014)

Company Filing History:


Years Active: 2001-2014

Loading Chart...
Loading Chart...
Loading Chart...
22 patents (USPTO):Explore Patents

Title: **Sophia Ran: Pioneering Cancer Treatment Innovations**

Introduction

Sophia Ran, based in Riverton, IL, is a prominent inventor recognized for her groundbreaking contributions to cancer treatment. With an impressive portfolio of 22 patents, she has developed innovative methods and compositions that target specific markers on tumor blood vessels, paving the way for advancements in cancer therapies.

Latest Patents

Among her latest patents, Sophia has introduced cancer treatment kits that utilize therapeutic antibody conjugates designed to bind to aminophospholipids. Her research uncovers the pivotal role of these phospholipids, such as phosphatidylserine and phosphatidylethanolamine, as stable and accessible markers on the luminal surfaces of tumor blood vessels. Notably, her invention offers aminophospholipid-targeted diagnostic and therapeutic constructs for effective tumor intervention. The methodologies detailed in her patents involve delivering therapeutic agents—including toxins and coagulants—specifically to these tumor blood vessels, leading to thrombosis, necrosis, and tumor regression.

Another significant patent involves the development of cancer treatment kits employing anti-aminophospholipid antibodies. Ran's discoveries highlight that the sole administration of these antibodies is sufficient to induce thrombosis and effectively cause tumor necrosis in vivo. The simplicity and effectiveness of using unconjugated anti-phosphatidylserine antibodies stands out within her innovative approaches, marking a crucial advance in the treatment of solid tumors.

Career Highlights

Sophia Ran has made notable strides in her career, having collaborated with esteemed institutions such as the University of Texas System and Board of Regents. Her work at these institutions has played a crucial role in pioneering research that bridges the gap between theoretical science and practical medical applications.

Collaborations

Throughout her distinguished career, Ran has worked alongside notable scientists, including Philip E. Thorpe and Rolf A. Brekken. Their collaborative efforts have not only bolstered her research but have also contributed significantly to the field of cancer treatment and the understanding of tumor biology.

Conclusion

Sophia Ran's innovative contributions to cancer treatment exemplify the potential of targeted therapeutic approaches in oncology. With her extensive array of patents and collaborative research efforts, she continues to influence the landscape of cancer therapies, aiming to improve patient outcomes and advance medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…